TY - JOUR
T1 - Brentuximab Vedotin in CD30-Positive Lymphomas
T2 - A SIE, SIES, and GITMO Position Paper
AU - Zinzani, Pier Luigi
AU - Corradini, Paolo
AU - Gianni, Alessandro M.
AU - Federico, Massimo
AU - Santoro, Armando
AU - Vitolo, Umberto
AU - Barosi, Giovanni
AU - Tura, Sante
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Brentuximab vedotin (BV) is approved for the treatment of patients with relapsed or refractory CD30-positive Hodgkin lymphoma, and relapsed or refractory systemic anaplastic large-cell lymphoma. Several uncertainties remain regarding the optimal use of the drug in its approved indications as well as outside them. This article reports recommendations on the use of BV issued during a consensus project, sponsored by the Italian Society of Hematology (SIE) and its affiliate societies, Società Italiana di Ematologia Sperimentale (SIES) and Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Scientific evidence on BV was evaluated by a panel of experts, and consensus was developed by group discussion for key questions selected according to the clinical relevance. The following key issues were addressed: testing CD30 positivity to assess eligibility to BV; assessing practice indications of BV in Hodgkin lymphoma and systemic anaplastic large-cell lymphoma; providing pretreatment evaluation of patients candidates to BV; monitoring the response to BV; managing patients treated with BV; and assessing the role of BV in other CD30-positive lymphomas.
AB - Brentuximab vedotin (BV) is approved for the treatment of patients with relapsed or refractory CD30-positive Hodgkin lymphoma, and relapsed or refractory systemic anaplastic large-cell lymphoma. Several uncertainties remain regarding the optimal use of the drug in its approved indications as well as outside them. This article reports recommendations on the use of BV issued during a consensus project, sponsored by the Italian Society of Hematology (SIE) and its affiliate societies, Società Italiana di Ematologia Sperimentale (SIES) and Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Scientific evidence on BV was evaluated by a panel of experts, and consensus was developed by group discussion for key questions selected according to the clinical relevance. The following key issues were addressed: testing CD30 positivity to assess eligibility to BV; assessing practice indications of BV in Hodgkin lymphoma and systemic anaplastic large-cell lymphoma; providing pretreatment evaluation of patients candidates to BV; monitoring the response to BV; managing patients treated with BV; and assessing the role of BV in other CD30-positive lymphomas.
KW - Brentuximab vedotin
KW - Consensus project
KW - Guidelines
KW - Hodgkin lymphoma
KW - Systemic anaplastic large-cell lymphoma
UR - http://www.scopus.com/inward/record.url?scp=84939565872&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939565872&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2015.06.008
DO - 10.1016/j.clml.2015.06.008
M3 - Article
C2 - 26195435
AN - SCOPUS:84939565872
SN - 2152-2669
VL - 15
SP - 507
EP - 513
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 9
M1 - 620
ER -